953 Indiana Street
About Glycomine, Inc.There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.
Founder and CEO: Agnes Rafalko
3 articles with Glycomine, Inc.
Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease
Glycomine, Inc. today announced that it has closed a $68 million Series B financing.
Glycomine, Inc. Announces $33 Million Series B Financing to Advance its Therapy for a Congenital Disease of Glycosylation
Glycomine, Inc., a biotechnology company focused on developing new therapies for rare diseases, today announced that it has raised $33 million in a Series B financing led by Novo Holdings A/S. Proceeds from the financing will be used to advance Glycomine's substrate replacement therapy for PMM2-CDG (CDG-1a
Glycomine Announces $12 Million Series A Financing To Advance A New Generation Of Replacement Therapies For Rare Diseases